DiaMedica Raises $4 Million from Fosun Pharma and SK Group

DiaMedica, a US-Canada biopharma, raised $4 million from China's Hermed Capital Healthcare Fund. Hermed was formed by Shanghai Fosun Pharma and SK Group, a South Korean conglomerate. DiaMedica is developing DM199, a purified form of recombinant tissue kallikrien (rhKLK-1) protein, which activates several metabolic pathways and, through vasodilation, improves blood flow. DiaMedical's DM199 is a proposed treatment for ischemic stroke and kidney disease. More details.... Stock Symbols: (TSX: DMA; OTCQB: DMCAF) (SHA: 600196; HK: 02196) Share this with colleagues: // //